Brief: Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter From The U.S. Food And Drug Administration For Adx-2191
26/06/2025 12:04
June 26 (Reuters) - Aldeyra Therapeutics Inc ALDX.O: ALDEYRA THERAPEUTICS RECEIVES SPECIAL PROTOCOL ASSESSMENT AGREEMENT LETTER FROM THE U.S. FOOD AND DRUG ADMINISTRATION FOR ADX-2191 FOR THE TREATMENT OF PRIMARY VITREORETINAL LYMPHOMA ALDEYRA THERAPEUTICS INC - CLINICAL TRIAL EXPECTED TO BEGIN IN SECOND HALF OF 2025 Source text: ID:nBw3SKSBLa Further company coverage: ALDX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Announces Intent To Submit Formal Dispute Resolution Request For Reproxalap To Treat Dry Eye Disease
Aldeyra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aldeyra Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora